Melatonin as a potential therapeutic agent in psychiatric illness

Maria D. Maldonado, Russel J. Reiter, Maria A. Pérez-San-Gregorio

Resultado de la investigación: Review articlerevisión exhaustiva

47 Citas (Scopus)


The aim of this review was to summarize the potential use of melatonin in the treatment of mental disorders, specifically bipolar disorders, depression, and schizophrenia. To date, melatonin has been most commonly used in psychiatry because of its hypnotic, rhythm resynchronizing, and antioxidant actions. Here, we examine other properties of the melatonin including its anti-inflammatory, antinociceptive, anxiolytic, and drug detoxification actions as well as its protective effects against neural loss. The brain is an intricate sensory and motor organ which receives information from both the external and internal environments. It transduces information into complex chemical and electrical signals which are transmitted throughout the central nervous system (CNS) and the organism. The pathogenesis of mental disorders remains ambiguous and neuroinflammation has been proposed as a causative agent. We consider the potential contributions of melatonin as therapeutic agent in CNS and during neuroinflammation in mental disorders.

Idioma originalEnglish (US)
Páginas (desde-hasta)391-400
Número de páginas10
PublicaciónHuman Psychopharmacology
EstadoPublished - 2009

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)


Profundice en los temas de investigación de 'Melatonin as a potential therapeutic agent in psychiatric illness'. En conjunto forman una huella única.

Citar esto